Andrew Combs Vice President at Incyte Corporation

Andrew Combs

Vice President at Incyte Corporation

LINKS

• https://www.linkedin.com/in/andrew-combs-4514413

  
  

  Summary

  Andrew P. Combs, Ph.D., joined Incyte in 2003 where he is currently Vice President of Discovery Chemistry. He has led medicinal chemistry programs in oncology and inflammation to >10 nomination candidates during his ~19 year tenor in the pharmaceutical industry. INCB024360 (Epacadostat) - an IDO1 inhibitor, INCB054329 - a BRD inhibitor, and INCB050465 - a PI3Kd inhibitor are currently being studied in human clinical trials for oncology. He is also responsible for the Discovery Analytical, Chemical Technologies, Chemical Informatics and the Computational Chemistry departments. Prior to Incyte, Dr. Combs was a Director at Bristol-Myers Squibb and Dupont-Merck where he led programs in the CNS area and founded a >50 member cross-functional target-directed Parallel Synthesis Team. Andrew’s research interests embrace the application of innovative technologies to expedite the drug discovery process, such as fragment-based approaches, structure-based drug design, parallel synthesis, microwave-assisted synthesis and automated LCMS purification methods. He has published >100 research articles/book chapters, been granted >30 patents, presented numerous invited lectures, served on editorial boards of three scientific journals (currently J. Med. Chem. Letters), co-chaired >10 ACS conferences, served on a variety of NIH review panels, and currently is a member of the SAB for Boston University CMD and the University of Delaware NIH-funded COBRE. Dr. Combs was a HHMI post-doctoral fellow in the laboratories of Prof. Stuart L. Schreiber at Harvard from 1994-1996 and holds a Ph.D. in Organic Chemistry from UCLA and BS degrees in Chemistry and Molecular Biology from the University of Wisconsin at Madison.

  Experience

  
  

  

  Vice President

  Incyte Corporation

  January 2003 – Present (13 years 4 months)
  

  Led medicinal chemistry team to the identification of the first-in-class immunotherapy drug, INCB024360 (Epacadostat), an inhibitor of indoleamine-dioxygenase-1 (IDO1). Non-exclusive collaborations with Merck, BMS, AZ and Genentech have been established to conduct Phase I/II oncology studies to evaluate the efficacy and safety of their respective anti-PD-L1 and anti-PD-1 immune checkpoint inhibitors, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, Epacodostat.
  
  Led medicinal chemistry team to the identification of INCB050465 (PI3Kd inhibitor) and INCB054329 (BRD inhibitor) which are currently in Phase I oncology studies.

  
  

  

  Director

  Bristol Myers Squibb

  2002 – 2003 (1 year)
  

  Concurrently the working group chair for the CRF1 Project, head of the Parallel Synthesis Group, head of the Peptide Synthesis Group, and oversaw a collaboration with Albany Molecular Research Institute (AMRI).

  
  

  Director

  DuPont - DuPont/Merck Pharmaceuticals

  April 1996 – August 2002 (6 years 5 months)
  

  Initiated and led a Parallel Synthesis group that discovered novel inhibitors for a broad range of drug targets in CNS, oncology, cardiovascular, and anti-microbial indications. The team was also responsible for the development and dissemination of innovative technologies to the medicinal chemistry department, including of parallel synthesis, microwave synthesis and preparative LCMS technologies.

  
  

  Education

  
  

  

  Harvard University

  Post Doctoral, Chemical Biology

  1994 – 1996
  

  Advisor: Prof. Stuart Schreiber
  
  Howard Hughes Medical Institute (HHMI) Post doctoral fellow

  
  

  

  University of California, Los Angeles

  Ph.D., Organic Chemistry

  1989 – 1994
  

  Advisor: Prof. Robert Armstrong
  
  "Synthesis and Structure-Activity Relationship Analysis of Dehydroamino Acid Derivatives Related to the Azinomycins", Andrew P. Combs, Diss. Abstr. Int. B 1994, 55(11) 4850.

  
  

  

  University of Wisconsin-Madison

  Bachelor of Sciences (BS), Double Major - Chemistry and Molecular Biology

  1984 – 1988
  

  Advisor: Prof. Robert McMahon

TEAMWORK

Incyte’s team (from left): Andrew Combs, Dilip Modi, Joe Glenn, Brent Douty, Padmaja Polam, Brian Wayland, Rick Sparks, Wenyu Zhu, and Eddy Yue.

Credit: Incyte

1st row:  Jingmei Shen, Benjamin Israel, and Aparna Sapara;
2nd row:  Andrew Combs (Incyte Biopharmaceutical Company), Joseph Keane (Muhlenberg College), 
               Bob Opila (Materials Science, UD), Ya-Ming Hou (Jefferson University) and Derrick Swinton (Lincoln University)

///////

Padmaja Polam

TEAMWORK

Incyte’s team (from left): Andrew Combs, Dilip Modi, Joe Glenn, Brent Douty, Padmaja Polam, Brian Wayland, Rick Sparks, Wenyu Zhu, and Eddy Yue.

Credit: Incyte

LINKS

http://www.pubfacts.com/author/Padmaja+Kasireddy-Polam

http://www.pubpdf.com/search/author/Padmaja+Polam

Dilip Modi

Associate Director, Pharmaceutical Development

https://www.linkedin.com/in/dilip-modi-251b644

Dilip Modi (@dmodi4) | Twitter

twitter.com

Experience

Associate Director, Pharmaceutical Development

Incyte

August 2015 – Present (9 months)Wilmington, DE

Senior Manager, Pharmaceutical Development

Incyte

August 2012 – August 2015 (3 years 1 month)

Manager, Pharmaceutical Development

Incyte

August 2010 – August 2012 (2 years 1 month)

Senior Scientist, Pharmaceutical Development

Incyte

February 2009 – August 2010 (1 year 7 months)

Senior Research Scientist, Pharmaceutical Development

Incyte

June 2007 – February 2009 (1 year 9 months)

Senior Staff Scientist, Discovery Chemistry

Incyte

January 2003 – June 2007 (4 years 6 months)

Research Associate, Discovery Chemistry

Bristol-Myers Squibb

October 2001 – December 2002 (1 year 3 months)

Research Associate, Discovery Chemistry

DuPont Pharmaceutical

June 1995 – October 2001 (6 years 5 months)

Education

University of Pennsylvania

Wharton Management Program

2000 – 2002

University of Delaware

BS, Chemistry

1991 – 1995

TEAMWORK

Incyte’s team (from left): Andrew Combs, Dilip Modi, Joe Glenn, Brent Douty, Padmaja Polam, Brian Wayland, Rick Sparks, Wenyu Zhu, and Eddy Yue.

Credit: Incyte

//////////

Trupti Sheth Director at Incyte

Trupti Sheth Director at Incyte

LINKS

https://www.linkedin.com/in/trupti-sheth-ab815514

https://www.google.com/patents/WO2015021153A1?dq=ininventor:%22Trupti+SHETH%22&cl=en
 https://www.facebook.com/trupti.sheth.1

Experience

Director

Incyte

August 2006 – Present (9 years 9 months)

Sr. Scientist

Cardinal Health

March 2002 – July 2006 (4 years 5 months)

Scientist

Celsis

October 2000 – February 2002 (1 year 5 months)

Analyst

Scientech lab

April 1999 – September 2000 (1 year 6 months)Bridge water NJ

Education

Devi Ahilya Vishwavidyalaya

BS

 

 

 

 

Hervé Hoppenot

Chairman, President, and Chief Executive Officer
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8000 employees in 50 countries. Mr. Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Barry P.  Flannelly, PharmD., MBA

Executive Vice President, General Manager US
Barry Flannelly joined Incyte as Executive Vice President, Business Development and Strategic Planning, in August 2014 and was appointed General Manager US in June 2015. Dr Flannelly has been working in oncology since 1987, and began his career in the pharmaceutical and biotech industry at Rhone-Poulenc Rorer, which later became Sanofi-Aventis. He has since had roles of increasing responsibility at Novartis Pharmaceuticals Corporation, Abraxis Oncology, Onyx Pharmaceuticals Inc., and Nektar Therapeutics. During his career, he has held positions in medical affairs, strategic planning, commercial operations, including head of sales and head of marketing, and business development. He earned his Doctor of Pharmacy from the University of Maryland School of Pharmacy, his Master in Business Administration from the University of Baltimore, and his Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy.

David W. Gryska, MBA

Executive Vice President, Chief Financial Officer
David Gryska joined Incyte as Executive Vice President and Chief Financial Officer in October 2014 and brings more than 30 years of finance experience to the Company. Before joining Incyte, Mr. Gryska served as Chief Financial Officer at both Celgene Corporation and Scios, Inc. From 1982 to 1993, Mr. Gryska worked at Ernst & Young, LLP. Mr Grsyka is a CPA and earned his MBA from Golden Gate University.

Reid M. Huber, PhD

Executive Vice President, Chief Scientific Officer
Reid M. Huber joined Incyte as a member of the founding scientific team in January 2002 and has more than 17 years’ experience in the pharmaceutical/biotech industry. For the past 13 years, Dr. Huber has held roles of increasing responsibility across multiple therapeutic areas in both Drug Discovery and Clinical Development at Incyte. In 2011, Dr. Huber assumed responsibility for the company’s research activities as Senior Vice President, Discovery Biology. Before joining Incyte, Dr. Huber held scientific research positions at DuPont  and Bristol-Myers Squibb Company from 1998 to 2002. Dr. Huber received his PhD in molecular genetics from the Washington University Medical School and held predoctoral and postdoctoral fellowships at the National Institutes of Health.

Richard S. Levy, MD

Executive Vice President, Chief Drug Development Officer
Richard Levy joined Incyte as Senior Vice President, Drug Development, in August 2003. Dr. Levy has more than 20 years of experience in the pharmaceutical and biotechnology sectors through his prior positions at Celgene Corporation, DuPont and Novartis Pharmaceuticals Corporation. Dr. Levy has extensive clinical research, regulatory, and product development skills and has worked in multiple therapeutic areas, including HIV, cancer and inflammation. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies at Celgene Corporation, where he was responsible for clinical development and regulatory affairs for the Cellular Therapeutics Division. Before Celgene Corporation, from 1997 to 2002, he was with DuPont first as Vice President of Regulatory Affairs and Pharmacovigilence and then as Vice President, Medical and Commercial Strategy. Dr. Levy received his MD from the University of Pennsylvania School of Medicine.

Eric H. Siegel, JD, MBA

Executive Vice President, General Counsel
Eric Siegel joined Incyte as the Chief Compliance Officer in October 2010 and became Executive Vice President and General Counsel in August 2011. Before joining Incyte, from April 2009 to October 2011, he was Chief Compliance Officer at EMD Serono, a privately held biotechnology company. From 2007 to 2009 he served as General Counsel for Solstice Neurosciences, also a privately held biotechnology company. He was Vice President, Deputy General Counsel and Chief Compliance Officer at Cephalon from 2004 to 2007. Mr. Siegel holds a B.A. from Franklin and Marshall College, his M.B.A. from Temple University and his J.D. from the University of Pennsylvania.

Steven H. Stein, M.D.

Senior Vice President, Chief Medical Officer
Steven Stein joined Incyte as Senior Vice President and Chief Medical Officer in March 2015, and has over 10 years of experience in clinical development and regulatory interactions. Dr. Stein joined Incyte from Novartis, where he most recently served as Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Oncology U.S. Dr. Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Steven earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa.

Paula J. Swain

Executive Vice President, Human Resources
Paula Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources. Prior to joining the company, Ms. Swain spent nearly 10 years with DuPont Pharmaceuticals Company (acquired by Bristol-Myers Squibb Company in 2001) where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank and Delaware Trust Company. Ms. Swain received her B.A. in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.

Wenqing Yao, Ph.D.

Executive Vice President, Discovery Medicinal and Process Chemistry
Wenqing Yao joined Incyte in February 2002 as Director, Chemistry. Dr. Yao has over 20 years of experience in medicinal chemistry. For the past nine years, Dr. Yao has held roles of increasing responsibility at Incyte, most recently as Senior Vice President, Discovery Chemistry. Prior to joining Incyte, Dr. Yao held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb Company from 1996 to 2002. Dr. Yao received his B.S. in chemistry from Xuzhou Normal University, his M.S. in organic chemistry from NanKai University and his Ph.D. in organic/medicinal chemistry from the University of Pennsylvania.

Hemavathi Gowda
Sr. Manager, Publications and Scientific Communications

//////////////